Lost Money on Alto Neuroscience, Inc. (ANRO)? You May Have Been Affected by Fraud- Contact Levi & KorsinskyAccesswire • 10/28/24
Alto Neuroscience, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Alto Neuroscience, Inc. (ANRO)Accesswire • 10/28/24
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Encouraged To Help The Schall Law FirmAccesswire • 10/26/24
Lost Money on Alto Neuroscience, Inc.(ANRO)? You May Have Been Affected by Fraud- Contact Levi & KorsinskyAccesswire • 10/23/24
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About PlatformBenzinga • 10/23/24
The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Alto Neuroscience, Inc. For Securities FraudAccesswire • 10/23/24
ANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 10/23/24
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive DisorderBusiness Wire • 10/22/24
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care AntidepressantsBusiness Wire • 09/04/24
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire • 08/13/24
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry ApproachBusiness Wire • 07/25/24
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive DisorderBusiness Wire • 07/16/24
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with SchizophreniaBusiness Wire • 06/20/24
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award WinnerBusiness Wire • 06/18/24
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire • 05/14/24
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific ConferencesBusiness Wire • 05/09/24
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaBusiness Wire • 04/23/24
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 04/09/24
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderBusiness Wire • 04/03/24
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsBusiness Wire • 03/21/24
Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS DisordersSeeking Alpha • 03/21/24